CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03260504
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:52.379023+00:00
Published At: 2025-12-08T00:00:00+00:00
Record Updated At: 2025-12-08
Results Posted At: 2025-12-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer", "Metastatic Clear Cell Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-08"
protocolSection.identificationModule.nctId: "NCT03260504"
protocolSection.identificationModule.officialTitle: "A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-12-08"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.